title: Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy.
abstract: This article examines the cost-effectiveness of chemotherapy (gemcitabine) versus nanotherapy (PEGylated liposomal doxorubicin) in the treatment of ovarian cancer. Significant differences in costs were mainly due to the initial drug costs, which were €1285.28 in favor of chemotherapy. These costs were more than offset by hospitalization costs, which were €2670.21 in favor of the nanotherapy. The cost per quality-adjusted life week (QALW) for the nanotherapy was estimated to be €220.92/QALW for the base case and ranged from €170-318/QALW based on model assumptions. The clinical benefit associated with nanotherapy was achieved, yielding not only positive cost-effectiveness results, but also, surprisingly, financial savings. Although more studies are necessary, this first comprehensive analysis supports the further use of nanotherapy for ovarian cancer.
authors.affiliation: Hasselt University, Department of Applied Economics, Martelarenlaan 42 - BE3500 Hasselt, Belgium.
authors.forename: Rita
authors.initials: R
authors.lastname: Bosetti
authors.forename: Gabriella
authors.initials: G
authors.lastname: Ferrandina
authors.forename: Wim
authors.initials: W
authors.lastname: Marneffe
authors.forename: Giovanni
authors.initials: G
authors.lastname: Scambia
authors.forename: Lode
authors.initials: L
authors.lastname: Vereeck
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D050997:Nanomedicine; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011092:Polyethylene Glycols / Q000191:economics / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; C506643:liposomal doxorubicin; D003841:Deoxycytidine; D011092:Polyethylene Glycols; D004317:Doxorubicin; D000093542:Gemcitabine
keywords: PEGylated liposomal doxorubicin; chemotherapy; cost–effectiveness; gemcitabine; nanotherapy; ovarian cancer; quality of life